These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 29106602)
1. PRMT5 as a druggable target for glioblastoma therapy. Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602 [TBL] [Abstract][Full Text] [Related]
17. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998 [TBL] [Abstract][Full Text] [Related]
18. T-Type Ca Visa A; Sallán MC; Maiques O; Alza L; Talavera E; López-Ortega R; Santacana M; Herreros J; Cantí C Cancer Res; 2019 Apr; 79(8):1857-1868. PubMed ID: 30755443 [TBL] [Abstract][Full Text] [Related]
19. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558 [TBL] [Abstract][Full Text] [Related]
20. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]